Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

NCT ID: NCT04191577

Last Updated: 2024-07-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 136 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-02
• Study Completion Date: 2021-12-13

Brief Summary

This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.

Detailed Description

Approximately 135 male and female subjects with Parkinson's disease, on a stable dosage of levodopa but with an average of ≥ 2 h total OFF time/day and not less than 1 h per day, will be enrolled. Following baseline safety and efficacy assessments, subjects will be randomized to receive once-daily doses of either low-dose CVN424, high-dose CVN424, or matching placebo. All subjects not randomized to placebo will initiate treatment with a low-dose of CVN424 on Day 1; the low-dose arm will continue to receive their low dose each day, while the high-dose arm will increase their daily dosage to the high-dose CVN424 beginning on Day 8 ±2 days and continuing thereafter. Study drug will be self-administered each morning as an oral suspension. Subjects will continue their other PD medications.

Conditions

Parkinson Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Placebo to be administered once daily.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

CVN424 (Low Dose)

Low dose of CVN424 to be administered once daily.

Group Type: ACTIVE_COMPARATOR

CVN424 Low Dose

Intervention Type: DRUG

CVN424

CVN424 (High Dose)

Patients randomized to the high dose will receive low-dose CVN424 once daily from day 1 to day 7, and will then increase their dose to the full high-dose once daily beginning on day 8.

Group Type: ACTIVE_COMPARATOR

CVN424 High Dose

Intervention Type: DRUG

CVN424

Interventions

CVN424 Low Dose

CVN424

Intervention Type: DRUG

CVN424 High Dose

CVN424

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Other Intervention Names

CVN424; CVN424

Eligibility Criteria

Inclusion Criteria

• Male or female adult who is 30 to 80 years of age inclusive at study entry.
• Has idiopathic Parkinson's disease, Hoehn and Yahr stages 2-4, and is on a stable dosage of levodopa.
• Experiences an average of at least 2 h total OFF time/day, and at least 1 h each day, per Patient Motor Diary over 2 days during Screening assessment.
• The subject signs and dates a written informed consent form (ICF) and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria

• Has atypical parkinsonism, severe disabling dyskinesia, or severe motor fluctuations that the investigator considers likely to interfere with study participation or assessments, or history of implant for Deep Brain Stimulation.
• Poor concordance (<75%) of self-report with site rater on in-clinic Screening period Patient Motor Diary. Subjects with low concordance may be retested after further instruction, at investigator's discretion.
• Screening period Patient Motor Diary scored at-home over 2 days demonstrates unacceptable quality of the diary, with more than 4 errors per day. (Assistance from caregivers is permitted if they also will be providing assistance with home Patient Motor Diary entries for Day 15 and 27 efficacy assessments.) Subjects with more than 4 errors per day may be retested after further instruction, at investigator's discretion.
• Body mass index (BMI) at Screening <18.0 or >35.0 kg/m2, inclusive.
• Subject has evidence of Clinically significant neurologic or other disorder or impairment that, in opinion of Investigator, is reasonably expected to impact the ability of the subject to participate or to confound the study results.
• Subject has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (i.e., a history of malabsorption, any surgical intervention known to impact absorption [e.g., bariatric surgery or bowel resection]).
• Subject has a history of cancer or other malignancy, with the exception of low-grade cervical intraepithelial neoplasia, low-grade (low-risk) prostate cancer, or 5-year cancer-free survivors of basal or squamous cell carcinoma, higher-grade cervical intraepithelial neoplasia or prostate cancer.
• Has a history of human immunodeficiency virus (HIV) infection.
• Subject has a supine blood pressure outside the ranges of 80 to 160 mm Hg for systolic and 50 to 100 mm Hg for diastolic, confirmed with up to two repeat tests, at the Screening Visit; or symptomatic orthostatic hypotension, in the opinion of the investigator.
• Subject has a resting heart rate outside the range 50 to 100 bpm, confirmed with up to two repeat tests, at the Screening Visit.
• Positive urine result for illegal drugs (except cannabis) at Screening, or history of illegal drug use (except cannabis) or alcohol abuse within 1 year prior to the Screening Visit.
• Subject has received any investigational compound (defined as a drug that has not been FDA-approved) within 30 days prior to the first dose of study medication, or within 5 half-lives of the investigational compound, whichever is greater.
• Subject has, within the prior month, ingested any excluded medication, supplements, or food products listed in the Excluded Medications and Dietary Products table as listed in Table 2.
• Male subjects who do not agree to all the following rules: when sexually active with female partner(s) of childbearing potential during the study and for 12 weeks after the last dose of study drug: a) use an acceptable method of birth control (condom with spermicide or surgical sterilization) and b) refrain from sexual activity with female partners who do not use an acceptable method of birth control. Barrier contraception (condom with spermicide) must be used by all male subjects who were not surgically sterilized at least 90 days prior to screening. Male subjects must also agree to refrain from sperm donation during the study and until 12 weeks after the last dose of study drug.
• Female subjects who are pregnant or breastfeeding or plan to become pregnant or donate ova during the study or for 30 days after the last dose of study drug. Women of childbearing potential (WOCBP) also must be practicing an adequate method of birth control (e.g., oral or parenteral contraceptives, intrauterine device, barrier, abstinence).
• Risk of suicide according to the investigator's clinical judgment or has made a suicide attempt in the previous 3 years.
• Subject is a study site employee or an immediate family member of a study site employee

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cerevance Beta, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Susan Kapurch

Role: STUDY_CHAIR

Cerevance, Inc.

Locations

Collaborative Neuroscience Network, LLC

Long Beach, California, United States

SC3 Research - Pasadena

Pasadena, California, United States

Parkinson's Disease and Movement Disorders Center of Boca Raton

Boca Raton, Florida, United States

Nova Clinical Research

Bradenton, Florida, United States

Premier Clinical Research Institute

Miami, Florida, United States

Parkinson's Disease Treatment Center of SW Florida

Port Charlotte, Florida, United States

Accel Research Site - Brain and Spine Institute of Port Orange

Port Orange, Florida, United States

USF Parkinson's Disease and Movement Disorders Center

Tampa, Florida, United States

Charter Research

Winter Park, Florida, United States

NeuroTrials Research, Inc.

Atlanta, Georgia, United States

Parkinson's Disease and Movement Disorder Center

Kansas City, Kansas, United States

Boston Clinical Trials

Roslindale, Massachusetts, United States

Quest Research Institute

Farmington Hills, Michigan, United States

Bio Behavioral Health

Toms River, New Jersey, United States

New York Neurology Associates

New York, New York, United States

M3 Wake Research

Raleigh, North Carolina, United States

Optimed Research Ltd

Columbus, Ohio, United States

Neurology Diagnostics Inc

Dayton, Ohio, United States

Prisma Health

Greenville, South Carolina, United States

Central Texas Neurology Consultants

Round Rock, Texas, United States

Inland Northwest Research, LLC

Spokane, Washington, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CVN424-201

Identifier Type: -

Identifier Source: org_study_id